Levodopa → Carbidopa

HRID 452338Notes

Reaction equation

C1C(C[C@H](N)C(O)=O)=CC(O)=C(O)C=1.C1C(C[C@H](N)C(O)=O)=CC(O)=C(O)C=1.[CH3:29][C@@:30]([NH:43][NH2:44])([C:40]([OH:42])=[O:41])[CH2:31][C:32]1[CH:33]=[CH:34][C:35]([OH:39])=[C:36]([OH:38])[CH:37]=1>>[CH3:29][C@@:30]([NH:43][NH2:44])([C:40]([OH:42])=[O:41])[CH2:31][C:32]1[CH:33]=[CH:34][C:35]([OH:39])=[C:36]([OH:38])[CH:37]=1

Participants

Reactant 2

HCID 6047Levodopa

HCID 104778Carbidopa-levodopa mixt.

Product 1

HCID 34359Carbidopa

Procedure

The in vitro dissolution profile of levodopa-carbidopa extended release capsules (from Example 3E), containing 200 mg levodopa and 50 mg carbidopa was obtained under simulated gastric conditions. The dissolution tests were performed in 900 mL of a 0.1 N HCl-pH 1.2 solution in a USP II apparatus at a temperature of 37° C. The paddle speed was set at 50 rpm. Samples of dissolution media were collected at predetermined intervals and analyzed by HPLC. The dissolution profiles of levodopa and carbidopa obtained from HPLC analysis are shown in FIG. 13.

Sources & evidence

ORD record: ord-63192a2fe1f54bafafb08780368c4579
Source dataset: uspto-grants-2013_07
DOI: 10.6084/m9.figshare.5104873.v1
Patent number: US08491929B2

Reaction notes

Loading…